Clinical Trial Patient Recruitment Services Market Size, Share, Growth, and Industry Analysis, By Type (Phase I, Phase II, Phase III and Phase IV ), By Application (Respiratory Diseases, Pain and Anesthesia, Oncology, Central Nervous System, Cardiovascular, Endocrine and Anti-Infective) and Regional Forecast to 2033

•   
•   
  

  Request a Free sample to learn more about this report

    

CLINICAL TRIAL PATIENT RECRUITMENT SERVICES MARKET OVERVIEW

The Accounts Payable and Accounts Receivable Software Market, valued at approximately USD 5 billion in 2024, is forecasted to grow consistently, reaching USD 5.35 billion in 2025 and ultimately achieving USD 9 billion by 2033, at a steady CAGR of about 7%.

Identification, sourcing, and education of persons for preliminary discussions about trial participation are  elements of patient recruiting in clinical trials. There is a need for this trial in this sector. This is very beneficial for the market.  All patient related actions that take place prior to the patient signing an informed consent form are included in this procedure. The trials are very important. Search for for and enrolling qualified people for clinical trials is known as patient recruitment. It is an important thing in medication development and health research as it influences the data reliability.

There is an increase in the number  of infectious and chronic disease problems in increasing in markets, and a growing number of diseases are the main factors driving the market's growth.  The market is growing due to this factor. There is agreat demand for this sector. There is a huge growth for this market due to its various uses and development in the future there is going to be a great market growth. The expansion of the market under study is thus anticipated to be driven by a rise in clinical studies for novel medication compounds. The Clinical Trial Patient Recruitment Services Market has grown as a result of this aspect.

KEY FINDINGS

COVID-19 IMPACT

Market Growth Obstructed by Pandemic due to Lockdown

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.

It first delayed and disrupted ongoing trials, it also gave patient recruitment services a chance to adapt and grow. There was a growth in the sector during this time period. People's knowledge about it and interest in clinical research grew as a result of the epidemic, and as a result, more people were prepared to take part in trials. The demand increased in this time for the product. In order to find and enrol people for COVID-19 vaccination trials and other pandemic-related investigations, patient recruiting services were essential. During the pandemic, there was a significant increase in the use of telemedicine platforms and digital recruitment tactics, which made distant patient interaction and recruitment possible.

LATEST TRENDS

High no. of Clinical Trials to Drive Market Growth

The safety and efficacy of the novel treatment are evaluated in clinical trials in comparison to established best practices. Trials are mainly focused on verifying and supporting the findings from the previous studies that indicate the medicine is a safe, practical, and efficient treatment for the designated indication. Theis  These clinical studies are either carried out to verify and amplify safety and efficacy findings from phase I and II trials, or they are carried out to assess the new drug's relative effectiveness regarding existing treatments. Consequently, the phase III market segment is anticipated to experience substantial expansion during the forecast period due to a high number of clinical trials reported in the area and the growing number of partnerships between leading market participants.

• According to the UK National Health Service NIHR, 1,045,282 participants were recruited to CRN‑supported clinical research in 2023/24, of which 24% (251,471) were first‑time research participants

• According to NHS England, participant recruitment to commercial clinical trials in the UK has declined by 44% over the past five years, underscoring shifting trial sponsor strategies

•   
•   
  

  Request a Free sample to learn more about this report

    

MARKET SEGMENTATION

By Type

Based on type the global market can be categorized into Phase I, Phase II, Phase III and Phase IV amongst which the leading segment is the  Phase I.

• Phase I: The security, side effects, ideal dosage, and timing of a novel medication are all examined in a phase I clinical trial.

• Phase II: About 100 to 300 volunteers participate in phase II studies to evaluate an investigational medication's efficacy for a specific ailment or condition.

• Phase III: Clinical studies in phase III assess the novel treatment's safety and efficacy in comparison to the accepted standard of care.

• Phase IV : Clinical trials in phase IV entail recruiting patients and are useful in determining the long-term stability and efficacy of a medication or treatment.

By Application

Based on application the global market can be categorized into Respiratory Diseases, Pain and Anesthesia, Oncology, Central Nervous System, Cardiovascular, Endocrine and Anti-Infective amongst which the leading segment is the Respiratory Diseases.

• Respiratory Diseases: Due to the requirements of certain patients, finding participants for clinical trials involving the respiratory system.

• Pain and Anesthesia: Due to pain and anesthesia the patients are trial are done.

• Oncology: There are ways to make patient recruitment in cancer clinical trials more effective.

• Central Nervous System: Patient recruitment and retention for clinical studies involving the central nervous system (CNS).

• Cardiovascular: As there are so many requirements for various studies, finding participants to participate in clinical trials for cardiovascular illness.

• Endocrine and Anti-Infective: The clinical trials are done for Endocrine and Anti-Infective.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.

Driving Factors

Rise in Investments to Boost the Market

With an emphasis on producing both unique and high-quality items, this industry is very R&D demanding. There is a growth in the market due to this prominent driver. Current patterns show that top pharmaceutical companies are increasing R&D productivity through collaborative research initiatives and significant  investment for long-term rewards. There are lots of uses by this product. A move toward completely integrated or operationally outsourced services that cover the full drug discovery and development process, from early stages growth to late-stage development phase, is being fueled by the growing R&D investments in the pharmaceutical companies and biopharmaceutical industries.

• According to NHMRC‑affiliated TrialsJournal research, 27% of all clinical drug trials are industry‑sponsored globally, fueling demand for specialized patient recruitment services

• According to the UK NIHR, its Research Delivery Network recruited over 1,000,000 participants in 2021/22—primarily for COVID‑19 vaccine and therapy trials—demonstrating expanded recruitment infrastructure capacity

Technological Advancements to Expand the Market

There is a growth in the market due to the technological factor.  Patient recruitment tactics are now more accurate and efficient because to the incorporation of cutting-edge technologies including data analytics and machine learning. There is a growth in the market as there is a great development in technologies. The development in technology are making growth in the market. Patient recruiting services are in high demand due to the increase in clinical trials being done.

Restraining Factor

Lack of Innovations to Impede Market Growth

As they work to produce innovative therapies and obtain patent exclusivity through expedited drug development, the biopharmaceutical and pharmaceutical sectors have seen a significant increase in competition. As the innovations are less the market is getting a loss in growth. The most commonly outsourced procedure in the context of science, manufacturing, and control (CMC) operations is bioanalytical testing, which is crucial to the pharma and biopharmaceutical development process at every stage. As the market innovations will increase the the market will grow. In order to satisfy regulatory requirements and obtain clearance for Investigational New Drug (IND) applications, CMC data is also crucial.

• According to NIH‑indexed analysis, 11% of research sites fail to enroll a single participant and 37% under‑enroll, leading to trial delays and protocol amendments

• According to the UK NHS, between 15% and 40% of patients drop out before study completion, complicating retention and data integrity

•   
•   
  Request a Free sample to learn more about this report

    

 REGIONAL INSIGHTS

The market is primarily segmented into Europe, Latin America, Asia Pacific, North America, and Middle East & Africa.

• North America 

Due to the largest number of pharmaceutical companies based in the US conducting the majority of their operations and clinical trials, rising R&D expenditures, and rising demand for drug research, North America is predicted to have considerable growth over the projected period. The market is expanding as a result of the growing number of clinical studies conducted in the area as a result of the presence of major industry players. For example, Walgreens started a clinical trial service to help pharmaceutical companies find and enroll patients.

KEY INDUSTRY PLAYERS

Key Players Focus on Partnerships to Gain a Competitive Advantage

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio.

• Antidote: According to Antidote, its Antidote Match™ platform powers trial matching for over 15 million patients per month across 250+ patient communities and health portals

• Clara Health: According to Clara Health, it can access 98% of all web traffic to enroll representative and diverse patient populations into trials via its decentralized recruitment platform

Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

List of Top Clinical Trial Patient Recruitment Services Companies

• Antidote (U.S.)
• Clara Health (U.S.)
• Clariness (Germany)
• BBK Worldwide (U.S.)
• Worldwide Clinical Trials (U.S.)

INDUSTRIAL DEVELOPMENT

November 2022: The end-of-treatment data from Amgen's Phase 2 OCEAN(a)-DOSE study of adult patients receiving experimental olpasiranwere presented. In individuals with established atherosclerotic cardiovascular disease , olapasiran was reported to lower lipoprotein(a) levels. AstraZeneca first revealed positive topline results from a Phase III study in ophthalmology, then positive data from two Phase III trials in breast cancer and rare blood condition.

REPORT COVERAGE

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, and restraints. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.